Developmental Current and Future Therapy for Severe Asthma
Pages 54-60 (7)
Severe or refractory bronchial asthma represents 5-10% of the asthmatic population that responds poorly to
high doses of inhaled corticosteroids. Biopharmaceutical approaches have identified new therapies that target key cells
and mediators, such as Th2-cells, cytokines, and chemokines. However, some of the clinical trials with these biologics in
patients with asthma have been unsuccessful, thus some of these studies had to be discontinued. This article will review
current therapeutic strategies of biological immune response modifiers in decreasing pathological immune responses.
Therapies using cytokine inhibitors currently provide a way to elucidate the role of individual cytokines in the
pathogenesis of human diseases and may yield new approaches to identifying asthma phenotypes.
Biological immunotherapeutics, bronchial asthma, personalized medicine, refractory severe asthma, pediatric patients, cytokine inhibitors, cytokines, human diseases, allergic airway, omalizumab
Division of Pulmonary Medicine, Allergy, and Rheumatology, Department of Internal Medicine, Iwate Medical University School of Medicine, Morioka, Japan.